Ophthotech Announces Leadership Transition Effective July 1, 2017

Source: Ophthotech

Ophthotech announced that David R. Guyer, MD, a cofounder, Chief Executive Officer and Chairman of the Board of Ophthotech, will transition to Executive Chairman effective July 1, 2017. Concurrent with this transition, Ophthotech’s Board of Directors appointed Glenn P. Sblendorio, the company’s President and Chief Financial Officer, as Chief Executive Officer, also effective July 1, 2017. Mr. Sblendorio will retain his role as President and has been nominated as a Class 1 director for election at the company’s upcoming annual meeting of stockholders. The company also announced the promotion of David F. Carroll to Chief Financial Officer and Treasurer, effective immediately. Mr. Carroll was previously Senior Vice President, Finance, of the company.

“I have confidence that under Glenn’s leadership as CEO the company will continue to execute on our plan to achieve the best results for shareholders in the near and long term,” Dr. Guyer said in a company news release. “I look forward to continuing to work closely with Glenn and the management team as the Executive Chairman of the Company.”

“As the company continues to review strategic alternatives and actively explores potentially obtaining rights to additional products, product candidates and technologies to treat ophthalmic diseases, particularly those of the back of the eye, David Guyer’s extensive expertise and experience brings a wealth of ophthalmology knowledge that is critical as we execute a strategy to maximize shareholder value,” stated Mr. Sblendorio. “In this newly created role of Executive Chairman, I look forward to David’s continued guidance and contributions to Ophthotech. Additionally, I look forward to working closely with Dave Carroll in his new position as Chief Financial Officer and to his continued contributions to the company.”

Related Content